Key result
A 6-month-old female with novel loss-of-function mutations in FLAD1 showed no clinical or biochemical improvement following treatment with low-dose riboflavin and a low-fat diet.
Why the study?
Mutations in FLAD1, encoding FAD synthase, have been reported in few patients with MADD-like phenotypes, but clinical features and treatment responses remain incompletely described.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
A novel case of FLAD1 loss-of-function mutations presenting with myopathy, scoliosis, and cataracts did not respond to low-dose riboflavin and a low-fat diet.
To the Editor Mutations in any of the genes involved in riboflavin metabolism may be associated to a clinical and biochemical phenotype compatible with multiple acyl-CoA dehydrogenation deficiency (MADD). Most patients show a defect of the electron transfer flavoprotein dehydrogenase (ETFDH) or a defect in the alpha (ETFA) or beta (ETFB) subunits of the electron transfer flavoprotein. In recent years, MADD has also been associated to other genes involved in the transport of riboflavin (SLC52A1, SLC52A2 and SLC52A3) or flavin adenine dinucleotide (FAD) (SLC25A32) and also in the synthesis of FAD (FLAD1). FLAD1 is a gene encoding for FAD synthase (FADS). In 2016, nine patients from seven unrelated families with biallelic mutations in FLAD1 were reported in a single publication. In addition, one of these patients was further followed up and more extensively described in a short report. Recently, a new family with two siblings diagnosed postmortem has been reported. Herein, we describe a female patient with two novel loss-of-function (LOF) mutations in FLAD1. At 6 months of age, she presented psychomotor delay associated with loss of gaze fixation and erratic eye movements, as well as hypotonia, low reaction to sound stimuli and reduced ability to object manipulation. Interestingly, this patient developed bilateral cataracts that have never been reported in patients with FADS deficiency, but it is difficult to prove that this clinical finding was due to the disease itself, as it can be due to many other causes. Urine organic acid profile showed an increase of ethylmalonate (25 mmol/mol creatinine, reference values: <10), and plasma acylcarnitine analysis revealed an increase of mediumand long-chain acylcarnitine species. We then assessed the production of acylcarnitines from H31-palmitate in cultured fibroblasts. Results showed an increase of short-, mediumand long-chain deuterated acylcarnitines that were suggestive of MADD, but molecular study of ETFA, ETFB, and ETFDH was negative. Treatment with low doses of riboflavin (3 mg/kg/day) and low-fat diet did not show any clinical or biochemical improvement. She was
No takes yet. Share an insight, caveat, or question.
García‐Villoria et al. (2018) conducted a case report in FLAD1 mutation (n=1). Riboflavin and low-fat diet was evaluated on Clinical or biochemical improvement. A 6-month-old female with novel loss-of-function mutations in FLAD1 showed no clinical or biochemical improvement following treatment with low-dose riboflavin and a low-fat diet.
Synapse has enriched 10 related papers. Consider them for comparative context: